Biotech | December 10, 2021
Aerogen partners with CanSinoBIO for aerosolised Covid-19 vaccine
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
